Continuous Blood Glucose Monitoring and automated therapeutic closed loop medical device for Intensive Care Units

Informazioni relative al progetto

ContiTRACE

ID dell’accordo di sovvenzione: 885877

DOI

10.3030/885877

Progetto chiuso

Data della firma CE 13 Novembre 2019

Data di avvio 1 Dicembre 2019

Data di completamento 30 Aprile 2020

Finanziato da

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

TRACE ANALYTICS GMBH
Germany

Periodic Reporting for period 1 - ContiTRACE (Continuous Blood Glucose Monitoring and automated therapeutic closed loop medical device for Intensive Care Units)

Periodo di rendicontazione: 2019-12-01 al 2020-04-30

Sintesi del contesto e degli obiettivi generali del progetto

Intensive Care Units (ICUs) require careful monitoring of blood glucose levels and insulin infusion to keep patients within physiologically safe glucose levels. Fluctuations on blood glucose are causally related to an increased risk of death and comorbidities. However, blood glucose monitoring (BGM) is currently performed by intermittent and manual offline analysis of blood samples. This technique proves inefficient (takes 17% caregivers time), costly (€300 per patient) and increments mortality in hospital ICUs by 40% due to irregular glucose level adjustments upon measurements. After 15+ years of experience in developing glucose monitoring sensors, we at TRACE are taking on our next big step to penetrate the medical device sector with ContiTRACE, an AI powered automated non-invasive medical device for continuous BGM.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

This Feasibility Study Report has proven the viability of developing ContiTRACE: a cutting-edge glucose measurement concept for ICUs, answering to patients, doctors and nurses’ requirements. This FS defines a Roadmap, Execution Plan, and Risk Analysis, comprising all necessary activities to scale ContiTRACE up to commercialisation. We have performed an in-depth analysis of the glucose monitoring devices market, and updated our Stakeholder Engagement, Commercial, Marketing, and IPR (including FTO analysis) Strategies. Finally, we have drafted Financial Forecasts on a 5-year-projection, based on a B2B business model and pricing policies.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

Our patented ContiTRACE will be able to measure glycaemic levels every 2 minutes and automatically infuse insulin when needed. It will be capable of self-calibrating and will have standardized body accesses, enhancing safety and minimising discomfort for the ICU patient. This will allow 1) caregivers to decrease their workload, 2) doctors to make informed decisions and 3) healthcare systems to optimize their limited human, economic and material resources as a result of the savings of over 50% of BGM related cost.

image-1.png